Premium
Modulation of ICAM‐1 expression by α‐MSH in human melanoma cells and melanocytes
Author(s) -
Morandini R.,
Boeynaems J. M.,
Hedley S. J.,
MacNeil S.,
Ghanem G.
Publication year - 1998
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/(sici)1097-4652(199806)175:3<276::aid-jcp5>3.0.co;2-l
Subject(s) - melanoma , forskolin , proopiomelanocortin , receptor , melanocyte , melanocyte stimulating hormone , endogeny , endocrinology , medicine , stimulation , biology , cancer research , chemistry
α‐MSH, a proopiomelanocortin (POMC)‐derived peptide, is known to be produced in the pituitary, the skin, and melanoma tumors and to possess many biological effects, mainly on melanocyte pigmentation and growth. Moreover, the melanocyte expresses adhesion molecules, including ICAM‐1. The latter has been reported to play a role in melanoma spread and associated metastatic process. We conducted a study in order to evaluate the possible effect of MSH on ICAM‐1 expression in human cultured malignant and normal melanocytes. Our data show that α‐MSH inhibits ICAM‐1 expression stimulated by TNF in a concentration‐dependent manner, both at the protein and gene expression level. Ninety percent inhibition was obtained with 10 nM MSH, while 50% inhibition was achieved with 1 nM. Endogenous cAMP elevation with forskolin as well as an exogenous cAMP stable analogue (Sp‐cAMPS) produced the same inhibitory effect. A screening of malignant melanocytes showed that inhibition of ICAM‐1 expression could be achieved only in those cells expressing detectable MSH receptors and seemed to correlate with the number of binding sites. In conclusion, our data strongly suggest α‐MSH as a potent inhibitor of ICAM‐1 expression in malignant melanocytes acting through MSH receptor stimulation and subsequent cAMP increase. J. Cell. Physiol. 175:276–282, 1998. © 1998 Wiley‐Liss, Inc.